← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Immunogenics, Llc
Newport Beach, CA
$6,896,837
Total funding
3
Grants
Funding over time
peak $2.2M · FY2017–23$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,896,837 · 3
By mechanism
U44$3,225,052 · 1
R44$2,204,433 · 1
R33$1,467,352 · 1
Investigators at Immunogenics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$998,618
U44 · FY2021 · AI
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$998,228
U44 · FY2020 · AI
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$977,604
R44 · FY2020 · DK
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$933,572
R44 · FY2021 · DK
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$728,593
U44 · FY2023 · AI
Latiglutenase as a Treatment for Celiac Disease$615,254
R33 · FY2018 · AT
Latiglutenase as a Treatment for Celiac Disease$592,996
R33 · FY2017 · AT
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$299,089
U44 · FY2019 · AI
A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$293,257
R44 · FY2019 · DK
Latiglutenase as a Treatment for Celiac Disease$259,102
R33 · FY2020 · AT
A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$200,524
U44 · FY2022 · AI